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Objective: Evaluate long-term results of autologous pericardial valved con-
duits in the pulmonary outflow. 
Methods: Between June 1983 and October 1993, 82 conduits were placed in
the outflow of the venous ventricle. Patients who received homografts (n = 2
patients), heterografts (n = 3 patients), and valveless conduits (n = 19
patients) and those patients who died within 90 days after the operation were
excluded. Fifty-four survivors of pulmonary outflow reconstruction with
fresh autologous pericardial valved conduits were followed up from 5 to 15
years (mean, 7.47 ± 2.8 years). Diagnosis include D-transposition of great
arteries (n = 16 patients), L-transposition of great arteries (n = 14 patients),
tetralogy of Fallot, pulmonary atresia with ventricular septal defect (n = 11
patients), truncus arteriosus (n = 10 patients), and double-outlet ventricle (n
= 3 patients). Implantation age ranged from 0.25 to 24 years (mean, 5.2 ± 4.2
years). Median conduit diameter was 16 mm. Two-dimensional echocardio-
graphic Doppler evaluations were made yearly; 9 patients underwent cardiac
catheterization. Reintervention for stenosis was indicated when the pressure
gradient exceeded 50 mm Hg. 
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Repair of many complex congenital heart malforma-tions requires the use of conduits to connect the out-
flow of the venous ventricle to the pulmonary artery. An
ideal valved conduit should comply with the following
requisites: (1) some potential for its diameter to increase
with time, (2) low likelihood of shrinkage or development
of intimal peel or thrombus, (3) long-lasting valve func-
tion, (4) ready availability, and (5) low cost. Many differ-
ent types of conduits have been used since Rastelli and
colleagues1 reported the use of a nonvalved pericardial
conduit in the outflow tract of a patient with tetralogy of
Fallot (ToF) and pulmonary atresia with ventricular sep-
tal defect (VSD) and since Ross and Somerville2 report-
ed the use of a homograft. The first patient with an
unvalved pericardial conduit, who has been followed up
for more than 30 years, has not had to undergo reopera-
tion.3 Follow-up of the different valved conduits showed
a high incidence of reoperations because of obstruction
caused by shrinkage, calcification, or outgrowth of the
conduit.4-7 After the wide experience with the use of
unpreserved pericardium in the reconstruction of the right
ventricular outflow tract in ToF, since June 1983 we have
been constructing a fresh autologous valved pericardial
conduit to connect the venous ventricle with the pul-
monary artery. The idea is to reproduce the excellent
long-term results of untreated autologous pericardial
patches and unvalved conduits, obtaining adequate valve
competence for the first postoperative months. 
After our original descriptions of the technique8-10
and the further publication of the short- and intermedi-
ate-term follow-up (mean, 4.2 years),11 this article
reports the results obtained after a mean of 7.47 ± 2.8
years in patients who received autologous pericardial
valved conduits (APVCs) during the first 10 years of
our experience.
Patients and methods
Patient selection. To have a follow-up of at least 5 years,
the patients selected for this study must have survived the
implantation of an APVC at least 3 months and must have
been operated on before December 1993.
Patient population. From June 1983 to October 1993, 82
conduits were placed in the pulmonary outflow tract.
Patients who received homografts (n = 2 patients), hetero-
grafts (n = 3 patients), or valveless conduits (n = 19
patients) and those patients who died within 90 days of the
operation were excluded. Thus 54 consecutive patients with
an APVC implanted were evaluated regarding the conduit’s
result. Mean follow-up time was 7.47 ± 2.8 years (range, 1-
13 years). Forty-nine patients were followed up for more
than 5 years, and 12 patients were followed up for more
than 10 years.
The mean age at operation was 5.25 ± 5 years (range, 0.25-
24 years; median, 5 years). The diagnoses of the patients
were D- transposition of the great arteries (D-TGA) with VSD
and left ventricular outflow tract obstruction (LVOTO) in 16
patients (30%); L-transposition of the great arteries (L-TGA)
with LVOTO with or without VSD in 14 patients (26%); trun-
cus arteriosus in 10 patients (19%); ToF with or without pul-
monary atresia, with or without major aortopulmonary collat-
eral supply in 11 patients (20%); and double-outlet right or
left ventricles 3 patients (5%; Fig 1). There were 28 male
patients and 26 female patients. 
The diameter of the conduits at the time of implantation
ranged between 12 and 20 mm and is given in Table I, togeth-
er with the age range. The median and mean diameter used
was 16 ± 2.13 mm.
Follow-up. All of the 54 hospital survivors could be traced
after hospital discharge. A questionnaire was mailed to the
patients and to the primary physician of the patients who
received follow-up at other institutions.
Postoperative evaluation included regular clinical exam-
ination at the outpatient clinic and chest radiographs every
6 months to search for conduit calcification. Two-dimen-
sional Doppler echocardiographic evaluation was per-
formed at regular yearly intervals as the method to assess
conduit diameter at the proximal, valvular, and distal lev-
els.12 Peak pressure gradients were measured at the three
levels of the conduit. When enlargement or reduction in
the diameter of the conduit was reported, the smallest
measured diameter was the one considered. Conduit
enlargement was defined when it occurred at all the three
levels of the conduit.
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Results: Three late deaths were unrelated to the conduit. Thirty-five autolo-
gous pericardial valved conduits increased in diameter (1-7 mm), remained
unchanged in 15 patients, and reduced 1 to 2 mm in 4 patients. The median
diameter was 18 mm at the last evaluation (P = .0001). Eight patients
required conduit-related reoperation 3 to 8 years after the implantation. Two
patients underwent balloon dilation of the autologous pericardial valved
conduit. No conduit had to be replaced. Freedom from reintervention at 5
and 10 years was 92% and 76%, being 100% at 10 years for conduits larger
than 16 mm at time of implantation. 
Conclusions: Autologous pericardial valved conduits show excellent long-term
results and compare favorably with other conduits. (J Thorac Cardiovasc Surg
2000;119:869-79)
A reoperation was considered conduit related when a distal
plasty, proximal plasty, or total conduit enlargement was per-
formed. The reoperation was considered unrelated to the con-
duit when no procedure was performed to it. The term con-
duit reintervention is used for both conduit-related catheter
interventions and surgical procedures. 
Statistical analysis. All values of continuous variables
were expressed as mean ± SD. The Kaplan-Meier method
was used to estimate the cumulative survival of patients and
survival of conduits that were free from reoperation and rein-
tervention. The Wilcoxon signed rank test was applied for
comparison between time-related variables. The statistical
analysis was performed with SSPS software (SSPS Inc,
Chicago, Ill) and STATA programs (Stata Corporation,
College Station, Tex).
Surgical technique. After the removal of the pericardium
from the right to the left phrenic nerves (leaving a 1-cm edge
to the nerve) and from the diaphragm to the reflection on the
aorta, the rectangular piece of tissue was placed on a wet
drape (saline solution). The diameter of the conduit is chosen
according to the patient’s body surface area.13 The conduit is
constructed according to the steps that have been previously
reported.8,9,11 The serous layer of the pericardium will be the
inner surface, and the fibrous pericardium will be the exter-
nal aspect of the conduit. The harvested pericardium is then
trimmed into two different geometric forms: a rectangle (the
future conduit) and a trapezoid (the future bicuspid valve).
The sizes of these pericardial forms are related to the diame-
ter of the conduit and thus to the patient’s body surface area.
The sizes are shown in Table II. 
The length of the rectangle is the measured distance from
the pulmonary artery orifice to the venous ventricular inci-
sion. The rectangle is secured to the wet drape with 4 stay
stitches at the angles. The trapezoid is superimposed on the
rectangle with its longer base (a´-a´) placed 5 to 6 mm from
the distal end of the rectangle (A-A). As a rule, the longer
base of the trapezoid (a´-a´) is always 10% longer than the
base of the rectangle (A-A). The trapezoid (valve) is secured
to the rectangle at 3 different points with 6-0 polypropylene
sutures. The serosal surface of the cusps is oriented to the
sinuses. Two stitches join a´ and A at both lateral ends, and a
third stitch is placed in the exact middle of both pericardial
pieces at point b (Fig 2, A, B, and C). The trapezoid is then
trimmed; 3 small triangular pieces are excised to achieve 2
semilunar cusps, leaving intact the union of both in a length
of 4 mm (commissure; Fig 2, D and E). Then the semilunar
cusps are sutured to the pericardial rectangle, with the sutures
used to secure the trapezoid at both lateral ends at a´ and in
the middle at b. On both lateral sides 4 mm of the suture are
on the edge of the rectangle (commissure) (Fig 2, E). Once
the valve is constructed, a Hegar dilator of the selected con-
duit diameter is placed over the pericardial rectangle with the
cusps (Fig 2, F). Then a 6-0 polypropylene double-running
suture is performed from the distal to the proximal end. This
suture is started 2 mm from the distal end to leave a wider
anastomotic orifice. The proximal end of this suture is left
untied because it will be adjusted according to the exact
length of the conduit at the time of the anastomosis to the
ventriculotomy (Fig 2, G and H). Once the intracardiac repair
is completed, the distal end of the conduit is sutured to the
pulmonary artery with 6-0 polydioxanone suture. This is
interrupted in the 4 quadrants and tied over the Hegar dilator
to prevent distal end narrowing. In the first 3 years of our
experience to 1986, distal narrowing at the time of tying the
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Fig 1. Relationship between diagnosis at operation, conduit-
related reoperation, and conduit-related transcatheter dilation.
TGA, Transposition of the great arteries; ToF, tetralogy of
Fallot; PA, pulmonary atresia; DOV, double-outlet ventricle.
Table I. Diameter of APVCs at implantation and at
last follow-up examination 
No. of 
Diameter (mm) patients Age (y)
At implantation*
12 4 0.25-5
14 14 0.4-6
15 2 4
16 12 1-9
17 7 1.4-10
18 11 4-24
20 4 5-8
At last follow-up†
11 1
13 1
14 3
15 8
16 6
17 6
18 8
19 4
20 4
21 7
22 3
23 1
24 1
*Median of the diameter was 16 mm; the mean diameter was 16 ± 2.13 mm.
†Median of the diameter was 18 mm; the mean diameter was 17.94 ± 2.96
mm. Wilcoxon signed-rank test, P < .0001.
sutures was the cause for distal stenosis. Since 1986 we have
increased the width of the distal end of the pericardial rectan-
gle by 4 mm, thus obtaining a wider anastomotic orifice (Fig
2, A-F). Then the proximal end of the conduit is sutured to the
ventriculotomy. In only 2 cases was a polytetrafluoroethylene
hood added to achieve an anastomosis without tension. In 8
selected cases, the pericardial sac was replaced with a poly-
tetrafluoroethylene* 0.1-mm pericardial membrane before
closing the sternotomy.
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Fig 2. APVC construction. Surgical technique. A, Pericardial trapezoid: a-a´ is the wider base; b is the midpoint,
and H is the height of the future valve (Table II). B, Pericardial rectangle (note the wider distal end): A-A´ is the
base of the rectangle; the trapezoid has been superimposed (note that the wider base of trapezoid [a-a´] is 10%
wider than the base of the rectangle [A-A´]). C, Three double-armed sutures have been placed to secure the trape-
zoid to the rectangle at A-a, A´-a´, and b to the midpoint of the rectangle. D, The form of the cusps is given by
trimming the 3 triangles at the base of the trapezoid. E, The running suture is performed from A and A´, suturing
the trapezoid to the edge of the rectangle in the first 3 mm and then from b to secure the cusps to the rectangle
(note that the first 3 mm of the suture stated at b is double). F, The pericardial rectangle with the cusps is wrapped
around the corresponding Hegar dilator. G, The conduit is closed with a 6-0 double running suture. The suture is
started at the distal end, and the proximal end remains untied. H, The completed valved conduit.
Table II. Size of the pericardium required, according to the selected conduit diameter
Rectangle Trapezoid
Diameter (mm) Width of pericardium (mm) Height of valves (mm) Lesser base (mm) Wider base (mm)
12.0 38.0 11.0 38.0 42.0 
14.0 44.0 12.5 44.0 48.5 
16.0 51.0 13.5 51.0 56.0 
18.0 56.5 15.0 56.5 62.0 
20.0 63.0 16.0 63.0 69.0 
*Gore-Tex; registered trade name of W. L. Gore & Associates, Inc,
Flagstaff, Ariz.
Forty conduits were placed to the left of the aorta. In 14
patients with L-TGA with dextroversion, the conduit was
placed to the right of the aorta.
The construction of the conduit takes a mean of 35 minutes
and is usually performed by a staff surgeon or a chief resi-
dent. During this time the main surgical team completes the
intracardiac repair of the malformation.
Results
Survival. No patients were lost to follow-up. There
were 3 deaths during the follow-up period. One patient
died of a brain tumor 8 years after conduit insertion,
another patient died of sepsis 5.8 years after the opera-
tion, and the third patient died suddenly 1.1 years after
the operation, probably of an arrhythmia caused by the
progression of pulmonary vascular disease, without
residual VSD or conduit obstruction.
The probability of patient survival (Kaplan-Meier)
for patients with APVC was 100% at 1 year, 98% at 2
and 5 years, and 92% at 10 years (Fig 3).
Conduit function. Doppler echocardiography in the
first postoperative months disclosed trivial or mild
valve regurgitation in 48 patients (88%), moderate
regurgitation in 5 patients (9%), and severe regurgita-
tion in 1 patient (2%). Pulmonary (conduit) valve
incompetence was disclosed by the finding of a moder-
ate diastolic murmur in most of the patients after 6 to
18 months of follow-up. 
The diameter of the conduits at the time of implan-
tation ranged from 12 to 20 mm with a median of 16
and a mean of 16 ± 2.13. At the time of most recent
evaluation, the diameter of the conduits in the 54
patients ranged from 11 to 25 mm, with a median of
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Fig 3. Kaplan-Meier patient survival estimate curve in the follow-up of APVC implantation, including 95% con-
fidence limits and the number of patients followed at each interval.
Fig 4. Freedom from conduit related reoperation estimate (Kaplan-Meier), including 95% confidence limits and
the number of patients followed up at each time interval.
18 mm and a mean of 18 ± 2.96 mm (P < .001,
Wilcoxon signed rank test).
At most recent measurement, the diameter of the con-
duit in 35 patients was 1 to 7 mm larger than at implanta-
tion; in 15 patients, the diameter of the conduit remained
unchanged; and in 4 patients, it had shrunk 1 to 2 mm.
The measured pressure gradients at late follow-up
ranged from 0 (6 cases) to 96 mm Hg. The median gra-
dient was 18.5 mm Hg. Only 8 patients showed gradi-
ents higher than 50 mm Hg. In these patients, reinter-
vention was indicated. In 28 patients (more than 50%
of the total group), the measured gradient was 20 mm
Hg or less.
Of the 54 patients, 8 patients underwent conduit-relat-
ed reoperations, and 2 patients underwent transcatheter
balloon dilation of the APVC; thus, 10 reinterventions
were performed. There were 4 non– conduit-related reop-
erations and 1 transcatheter distal left pulmonary artery
stent implantation. Conduit reoperations were performed
3 to 8.2 years after the initial operation. The probability
of freedom from reoperation for the whole group at 1
year and 2 years was 100%, 96% at 5 years, and 80% at
10 years (Fig 4). Four of the reoperations were due to dis-
tal suture stenosis, all in patients who had undergone the
operation before 1986. Later, the distal end of the conduit
was enlarged as described; the suture was performed in 4
quadrants and tied over a Hegar dilator. 
Conduit reoperations were indicated according to the
gradient in the pulmonary outflow tract. The venous
ventricular–pulmonary artery gradient in the 8 patients
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Fig 5. Freedom from conduit-related reintervention estimate, according to diagnosis. TGA, Transposition of the
great arteries; DOV, double-outlet ventricle; ToF, tetralogy of Fallot.
Fig 6. Freedom from conduit-related reintervention estimate for the whole group, including 95% confidence lim-
its and the number of patients followed up at each time interval.
ranged from 30 to 96 mm Hg, with a mean of 67 mm
Hg. Even though reoperation was indicated with gradi-
ents higher than 50 mm Hg, 1 patient with a gradient of
only 30 mm Hg underwent conduit revision because of
the coexistence of an LVOTO.
None of the obstructions were found to be at the valvu-
lar level. In fact, in 6 patients who underwent reoperation
later than 1 year after conduit insertion, the valve could
not be identified, although it was found pliable in all of
the patients who underwent reoperation because of
residual malformations unrelated to the conduit in the 6
postoperative months. The valves were found to be pli-
able between 4 and 6 months after implantation. 
The relationship between preoperative diagnosis,
conduit-related reoperation, and catheter dilation is
shown in Fig 1. 
Three of the 10 patients with truncus arteriosus
underwent reoperation because of conduit stenosis, and
1 patient underwent reoperation because of distal end
stenosis. The median age of these patients at the initial
operation was 6 months. These 3 patients underwent
reoperation 6 to 7.25 years after the initial operation.
Three of the 16 patients with D-TGA underwent reop-
eration 3 to 7.75 years after the initial insertion of the
conduit. One of the reoperations was due to distal
suture stenosis.
One patient with ToF and either double-outlet right
or double-outlet left ventricle underwent conduit-relat-
ed reoperations because of distal-end stenosis 8 and 5
years after conduit insertion. None of the patients with
L-TGA required a reoperation or catheter intervention
because of conduit stenosis. 
Of the 8 conduit-related reoperations, 4 reoperations
were distal-end suture stenosis; in the other 4 reopera-
tions, the conduit was uniformly restrictive, but the
patient had outgrown the conduit. In those patients who
required reoperation, the entire length of the conduit
was augmented with a polytetrafluoroethylene patch in
4 patients; distal plasty was performed in the other 4
patients. In 3 of the reoperations, some degree of con-
duit calcification was observed.
The freedom from reintervention estimates by preop-
erative diagnosis (Kaplan-Meier) are shown in Fig 5.
The log-rank test for equality showed that time to reop-
eration differs by diagnostic group (P = .02). However,
when the group of double-outlet ventricles (n = 3
patients) is eliminated, there is no significant difference
among D-TGA/L-TGA/truncus and ToF (P = .18). 
Two patients were subjected to transcatheter balloon
dilation 4 and 4.33 years after the conduit insertion. In
both cases a distal-end stenosis was relieved success-
fully, and the pressure gradients dropped from 45 to 12
mm Hg and 96 to 23 mm Hg. The freedom from rein-
tervention estimate (Kaplan-Meier) for the whole
group showed 100% at 1 and 2 years, 92% at 5 years,
and 76% at 10 years (Fig 6). In 1 additional patient, a
stent was inserted distally in the left pulmonary artery
but was unrelated to the conduit.
The relationship between diameter of the conduit at
implantation and conduit-related reoperation/reinterva-
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Fig 7. Freedom from conduit-related reintervention estimate (Kaplan-Meier), according to size groups: group I,
conduit diameter 16 mm or smaller, and the estimated probability of freedom from reintervention at 4 years is
97% (95% confidence limits, 0.80, 1.0), although at 8 years it is 0.67% (95% confidence limits, 0.45, 0.82); group
II, conduit diameter larger than 16 mm, which includes the number of patients followed up at each interval of
time, and the estimated probability of freedom from reintervention at 4 years is 1% (95% confidence limits, 0.96,
1.0). At 8 years the lower confidence bound is 0.92. Confidence limits overlap at 4 years but not at 8 years.
tion rate was analyzed. Because the median conduit
diameter at the time of insertion was 16 mm, 2 groups
were compared: group I, 32 patients (59%) with diam-
eters equal to or less than 16 mm; group II, 22 patients
(41%) with conduits larger than 16 mm in diameter.
All the reinterventions (catheter and surgical opera-
tions) were performed on group I patients. Thus, no
patient with a conduit larger than 16 mm at the time of
implantation had to undergo reoperation. The Kaplan-
Meier reoperation-free conduit survival estimates (Fig
7) show that time to reoperation is shorter for patients
with conduit size equal to or less than 16 mm (P = .07).
In patients who underwent reoperation, a small biopsy
specimen of the conduit tissue was sent for pathologic
examination. These specimens were consistently
reported as having a cellular matrix with two layers,
one endothelialized neointima and one fibrous with
collagen and fibroblasts.
Discussion
The use of valved conduits has become a common
procedure in the correction of congenital heart disease.
TGA (either D-TGA or L-TGA) with VSD and LVOTO,
ToF with pulmonary atresia, ToF with anomalous coro-
nary artery, double-outlet right ventricle, double-outlet
left ventricle, and truncus arteriosus are the malforma-
tions in which these conduits are used to achieve
venous ventricle–pulmonary artery continuity. Cryo-
preserved homografts have replaced heterografts as the
conduit of choice in the past 2 decades. Good short-
term results have been obtained with homografts,12,14,15
but the long-term results are disappointing.5-7,13
Furthermore, in the long term, the results of homografts
are comparable with those of heterografts.16,17 Even the
valve function of homografts did not show a substantial
difference with heterografts in the long term, and the
failure rate was almost 100% when they were used in
the pulmonary outflow tract, as recently reported.18,19
When present, obstruction in homografts most fre-
quently occurs at the valvular level, necessitating trans-
catheter balloon dilation and/or stent implantation,
which carries the unavoidable consequence of pul-
monary regurgitation.19 Heterografts, on the other
hand, have the early disadvantage of bleeding; their use
is inadequate in neonates and infants with thin and fri-
able pulmonary arteries and coronary compression by
the valve ring. Late failure is mostly associated with
peel tissue ingrowth, valve degeneration/calcification,
and obstruction.17,20
After long experience and excellent results achieved
by pericardial patching of the right ventricular outflow
tract21 and the use of nonvalved pericardial conduits for
ToF and pulmonary atresia,1 we designed an autolo-
gous valved pericardial conduit. Autologous unpre-
served pericardium has been shown to be a durable tis-
sue that is pliable and easy to handle and suture. Our
aim was to construct a valved conduit that would com-
bine the advantage of good pulmonary valve function
during the first months after repair, when it is crucial,
and long-term conduit durability.
These conduits offer several advantages, including
low cost, easy construction, absence of antigenicity,
capability of increasing its diameter, no need for steril-
ization, and stent-free design. 
With the present trend to reduce costs in the devel-
oped countries and the importance of low cost and
availability in developing countries, the option of an
APVC is attractive. It has two advantages when cost is
considered: (1) The conduit is custom-made for the
patient with his own tissue; all that is needed are 4 to 6
sutures of 6-0 polypropylene plus a few stay sutures
and 35 minutes of time for one surgeon. (2) Costs are
greatly reduced by the fact that the incidence of conduit
reoperation is low. 
APVCs have demonstrated an increase in diameter
with time. In 35 of the 54 conduits in this series, the
diameter increased 1 to 7 mm. We do not consider
this increase in diameter as real growth, because
there was no evidence of cellular proliferation.
Nevertheless, this increase in diameter is a unique
feature of these conduits. The long-term results have
been excellent. A freedom from reoperation of 80%
at 10 years compares favorably with data on all other
available conduits. Lacour-Gayet and colleagues22
and Kreutzer23 have reported 100% freedom from
reintervention at 7 years using APVCs constructed
with this technique in patients with truncus arterio-
sus. This is somewhat similar to our own experience
with the same malformation.
Even though 3 of the 10 patients with truncus arte-
riosus had to undergo reoperation, these were the
patients with the smallest conduit diameters, ranging
from 12 to 16 mm (median, 14 mm). Another addition-
al benefit is that none of the patients who underwent
reoperation had to have the conduit replaced, just
enlarged. This confers an additional advantage. The
patients with distal-end suture stenosis needed only
distal-end patch augmentation at reoperation.
The construction of the valved conduit has a learning
curve. Because the conduit is an essential part of the
correction of these complex malformations, the conduit
construction should be precise. The sizes in Table II
should be strictly followed. The training in manufac-
turing and testing of this type of conduit may be per-
formed in the animal laboratory as reported by Chiu,24
Kumar25 and their colleagues.
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At the time of implantation, the placement of the dis-
tal polydioxanone suture in 4 quadrants and over a
Hegar dilator is crucial. Four patients in the initial part
of our experience had to undergo reoperation because
of distal-end stenosis. 
One disadvantage of this technique is that it is usual-
ly not possible to harvest pericardium when adhesions
from previous operations are present. Despite this, we
were able to do so in one patient with a double-outlet
right ventricle of the Taussig-Bing type, in whom a pul-
monary band and repair of a coarctation had been per-
formed 8 months before conduit implantation.
However, we are certain that this is the exception, not
the rule.
The short period of competence of the APVC valve is
a relative disadvantage. Pulmonary competence in the
immediate postoperative period is associated with bet-
ter outcome,26 and pulmonary regurgitation is mostly
well tolerated in the late outcome if not associated with
other residual defects such as VSD, distal stenosis or
pulmonary hypertension, and tricuspid regurgitation.
Although pulmonary incompetence for more than 20
to 30 years has been shown to have a deleterious
impact on right ventricular function, all other conduits
necessitate numerous reoperations in that period of
time, affecting the right ventricle because of systolic
pressure overload. On the other hand, patients who
have undergone L-TGA will probably withstand pul-
monary incompetence better because of the underlying
left ventricle. 
When pulmonary valve function is essential, as in
ToF with pulmonary atresia and peripheral stenosis and
in patients with severe pulmonary hypertension caused
by pulmonary obstructive disease, the use of these con-
duits is not advocated. In such patients the use of
homografts is preferred.
Even though we did not use the APVC for pulmonary
autograft aortic valve replacement27 in the time frame
of this series, it may be the conduit of choice for right
ventricular outflow tract reconstruction. Recently,
Garcia and colleagues28 reported the use of APVCs in
9 such operations without any conduit-related reopera-
tions during follow-up.
Limitations of the study. Even though we report the
use of these conduits in a variety of lesions, the number
of patients in each group precludes the identification of
predictors of failure by multivariate analysis.
Therefore, some of the statistical differences may be
due to chance alone.
Conclusion
The use of APVCs in the venous ventricular outflow
tract has shown very good results, and it proved to be
the definitive conduit for more than 80% of the patients
in the long term.
We thank Kimberlee Gauvreau, ScD, for the statistical
analysis in this report and Richard A. Jonas, MD, for his
sponsorship.
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Discussion
Dr William G. Williams (Toronto, Ontario, Canada). I
congratulate the group from Buenos Aires for focusing our
attention on an important cause of morbidity and mortality
in congenital heart disease, the extracardiac valved conduit.
As Mr de Leval has said, the extracardiac valved conduit is
a time bomb. In our experience with more than 1000 valved
conduits, the overall reoperation rate within 10 years of
implantation is about 50%. Reoperation rates are much high-
er in younger patients with smaller conduits and, conversely,
much better in mature patients, approaching 90% conduit sur-
vival at 10 years. Your data confirm this trend when you
report that the conduits under 16 mm in diameter fare less
well than those with larger conduits. 
Because the age of the patient and the size of the conduit
are so important in determining durability, it is difficult to
accept your conclusion regarding improved durability with-
out age- and size-matched controls of other conduits.
Nevertheless, your conduit has been quite successful. 
Failure of valved conduits is almost invariably the result of
progressive stenosis, and most commonly the stenosis occurs at
the valve. It is a paradox that the success of your valved conduit
is due to the disappearance of the valve leaflets within about 6
months of implantation. The patients are left with a nonvalved
conduit, thereby avoiding the most common reason for reoper-
ation, valve stenosis. Fortunately, the outlook for patients with
no pulmonary valve and an otherwise normal heart is a 20- to
30-year interval free of symptoms. Later in life, a pulmonary
valve will be necessary for adequate right heart function. 
Why do the leaflets disappear? The monocusp leaflet used
occasionally in ToF repair also seems to disappear. In both
situations the reconstructed outflow tract lacks a sinus of
Valsalva. The sinus of Valsalva is an important part of the
valve mechanism. It prevents the leaflet from touching the
arterial wall in systole and, importantly, it initiates its move-
ment toward the closed position at end-systole. 
Have you considered ways of making the leaflets more
durable? Specifically, would incorporating a sinus of Valsalva
in the prosthesis make the leaflets last longer? Would other
leaflet material be more durable without the risk of stenosis,
for example, glutaraldehyde-treated autologous pericardium? 
You outline your indications and contraindications. Are
there other factors that might lead you to not use this very
inventive pericardial conduit? 
Dr Schlichter. To address your question about sinuses, we
have not planned to build sinuses into it. Autologous unpre-
served pericardium is a very soft tissue, and it will probably
not maintain the form of a sinus of Valsalva. What we have
considered is to use glutaraldehyde-preserved valves, and we
did so in 1 case. However, that approach goes against our phi-
losophy because it will probably preserve the valve, but the
valve will probably calcify. We prefer the vanishing valves
instead of the stenotic valves, and that is why we did not con-
sistently try to preserve the valves. 
Dr Radu C. Deac (Tirgu-Mures, Romania). Contrary to
the hopes of many cardiovascular surgeons, the long-term
fate of fresh, untreated autologous pericardium used in the
bloodstream so far, in experimental and clinical cases, was
fibrosis, shrinkage, and calcification. 
Your results are much different concerning the conduit, not
the valve. Do you have any histologic information about the
structure of the autologous pericardium of the conduit or of
the leaflets in those replaced or retrieved? Does the difference
in size (which you showed) indicate growth or dilatation? Is
there any evidence about the revascularization of the tube of
the conduit? Your results showed that the autologous peri-
cardium, although not ideal, is the best available tissue in the
right side of the heart. 
Dr Schlichter. We have evaluated histologic information. We
consistently found that the pieces sent to pathology during reop-
eration showed an intimal layer of neointima and cellular matrix
with fibroblasts and collagen tissue. I believe the reason that we
did not see shrinkage is that the pericardium used in the arteri-
al circuit behaves differently than it does under atrial pressures. 
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We do not consider the conduit enlargement to be growth
but simple dilation. Growth would presuppose cellular prolif-
eration, and we could not identify that. 
Regarding revascularization, we observed invasion of
neovessels into the pericardium in one patient. This was a
patient who underwent reoperation approximately 11⁄2 years
after the initial operation. 
Dr C. E. Anagnostopoulos (New York, NY). It has long
been known that the tensile strength and compliance of var-
ious tissues lag far behind those of the cardiovascular sys-
tem, particularly pericardium, dura mater, and fascia lata.
By contrast, the rectus sheath is virtually an identical
match to aortic valve and aorta. We now have long-term
results in 7 patients in whom rectus sheath was used on the
right and left sides. We have seen that it becomes virtually
an aorta, with many layers and cells, and it can grow, in
contrast to the pericardium, which does not. My question is
whether in your experience, since 1993, you have modified
the type of valve that you are using and whether you have
considered using valveless conduits. 
Dr Schlichter. We did not change the type of the valve that
we used. We continued following exactly the same proce-
dures. The only thing we changed in the whole 15 years is
that we are now tying over the dilator and are doing our sutur-
ing within 4 quadrants with polydioxanone suture. We are
presently not using a nonvalved conduit because we believe
that pulmonary valve competence is important in the first
postoperative weeks. We always try out the conduits to make
sure they do not leak a single drop. 
Dr Francois Lacour-Gayet (Paris, France). We have used
the APVC to repair truncus arteriosus in small-weight infants
and have been satisfied with the long-term results. We had to
reoperate on 1 patient after 10 years; the diameter of the con-
duit had not expanded from its 12-mm size when it was ini-
tially inserted. It had not grown, but it has not shrunk; the
valve was absent.
I must say that I hope this worked, because what we do
when we repair the pulmonary artery with fresh native peri-
cardium in the arterial switch operation is not very different.
In many patients, after total harvesting of two sinuses of
Valsalva, we end up with a very small arterial wall. I suspect
that reonstructing the pulmonary artery with pericardium in
the arterial switch operation is quite similar to what you do
when you construct a pericardial conduit from the right ven-
tricle to the pulmonary artery. Therefore, I support this tech-
nique, and I believe that it could be useful in places in which
small-sized homografts are not available or in countries
where homografts are unavailable.
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